1 Clinical Outcomes Working Group. Clinical outcome indicators. Edinburgh: Clinical Resource and Audit Group; 2000. [cited 4 Nov 2002]. Available from url: http://www.show.scot.nhs.uk/indicators/Outcomes/OutcomesReport2000.pdf [section 1.1] [section 1.2]

2 ISD Scotland. Cancer incidence and mortality by site/type of cancer, sex and year of diagnosis/registration of death: 1989-1998. Edinburgh: ISD Scotland; 2000.

3 ISD Scotland. Key health topics. Cancer. Facts and figures. Colorectal (or large bowel) cancer.

4 Muir CS, McKinney PA. A strategy for cancer control in Scotland. Glasgow: Scottish Forum for Public Health Medicine; 1994.

5 Berrino F, Capocaccia R, Estève J, Gatta G, Hakulinen T, Micheli A, et al., editors. Survival of Cancer Patients in Europe: the EUROCARE-2 Study. Lyon: International Agency for Research on Cancer; 1999.

6 Gatta G, Faivre J, Capocaccia R, Ponz de Leon M. Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 1998;34:2176-83.

7 Bergström A, Pisani P, Tenet V, Wolk A, Adami H. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421-30.

8 Michels KB, Giovannucci E, Joshipura KJ, Rosner BA, Stampfer MJ, Fuchs CS, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst 2000;92:1740-52.

9 Potter J, editor. Food, nutrition and the prevention of cancer: a global perspective. London: World Cancer Research Fund; 1997. [section 2.1.2] [section 2.4]

10 Kim YI. AGA technical review: impact of dietary fiber on colon cancer occurrence. Gastroenterology 2000;118:1235-57.

11 Byers T. Diet, colorectal adenomas, and colorectal cancer. N Engl J Med 2000;342:1206-7.

12 Sandhu MS, White IR, McPherson K. Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. Cancer Epidemiol Biomarkers Prev 2001;10:439-46.

13 Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer 2002;98:241-56.

14 IARC Working Group on the Evaluation of Cancer Preventive Agents. Carontenoids. Lyon: International Agency for Research on Cancer; 1998.

15 Kiningham RB. Physical activity and the primary prevention of cancer. Prim Care 1998;25:515-36.

16 Colditz GA, Cannuscio CC, Frazier AL. Physical activity and reduced risk for colon cancer: implications for prevention. Cancer Causes Control 1997;8:649-67.

17 Friedenreich CM. Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev 2001;10:287-301.

18 IARC Working Group on the Evaluation of Cancer Preventive Agents. Weight control and physical activity. Lyon: International Agency for Research on Cancer; 2002.

19 Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001;10:725-31.

20 Corrao G, Bagnardi V, Zambon A, Arico S. Exploring the dose-response relationship between alcohol consumption and the risk of several alcohol-related conditions: a meta-analysis. Addiction 1999;94:1551-73.

21 Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gen Based Med;1999:1155-66.

22 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomised controlled trial. JAMA 2002;288:321-33.

23 Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 1998;7:653-9.

24 Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-82.

25 Beral V, Banks E, Reeves G, Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999;4:191-215.

26 Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93:880-8.

27 Franceschi S, La Vecchia C. Colorectal cancer and hormone replacement therapy: an unexpected finding. Eur J Cancer Prev 1998;7:427-38.

28 IARC Working Group on the Evaluation of Cancer Preventive Agents. Non-steroidal anti-inflammatory drugs. Lyon: International Agency for Research on Cancer; 1997.

29 Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998;317:559-65. [section 2.7.1] [section 5.1]

30 Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7. [section 2.7.1] [section 2.7.3]

31 Rhodes JM. Colorectal cancer screening in the UK: Joint position statement by the British Society of Gastroenterology, The Royal College of Physicians, and The Association of Coloproctology of Great Britain and Ireland. Gut 2000;46:746-8.

32 Steele RJ, Parker R, Patnick J, Warner J, Fraser C, Mowat NA, et al. A demonstration pilot trial for colorectal cancer screening in the United Kingdom: a new concept in the introduction of healthcare strategies. J Med Screen 2001;8:197-202.

33 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.

34 Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994;35:1590-2.

35 Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642. [section 2.7.2] [section 2.7.3] [section 4.1] [section 10]

36 Bond JH. Colorectal cancer update. Prevention, screening, treatment, and surveillance for high-risk groups. Med Clin North Am 2000;84:1163-82. [section 2.7.2] [section 2.7.3]

37 van Stolk RU, Beck GJ, Baron JA, Haile R, Summers R. Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The Polyp Prevention Study Group. Gastroenterology 1998;115:13-8.

38 Lund JN, Scholefield JH, Grainge MJ, Smith SJ, Mangham C, Armitage NC, et al. Risks, costs, and compliance limit colorectal adenoma surveillance: lessons from a randomised trial. Gut 2001;49:91-6.

39 Thiis-Evensen E, Wilhelmsen I, Hoff GS, Blomhoff S, Sauar J. The psychologic effect of attending a screening program for colorectal polyps. Scand J Gastroenterol 1999;34:103-9.

40 Wardle J, Taylor T, Sutton S, Atkin W. Does publicity about cancer screening raise fear of cancer? Randomised trial of the psychological effect of information about cancer screening. BMJ 1999;319:1037-8.

41 Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetsky S, Schmale AM, et al. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249:751-7.

42 Fallowfield L, Ratcliffe V, Jenkins V, Saul J. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer 2001;84:1011-5.

43 Slevin ML, Nichols SE, Downer SM, Wilson P, Lister TA, Arnott S, et al. Emotional support for cancer patients: what do patients really want? Br J Cancer 1996;74:1275-9.

44 Harrison J, Haddad P, Maguire P. The impact of cancer on key relatives: a comparison of relative and patient concerns. Eur J Cancer 1995;31A:1736-40.

45 Baider L, Koch U, Esacson R, De-Nour AK. Prospective study of cancer patients and their spouses: the weakness of marital strength. Psychooncology 1998;7:49-56.

46 Northouse LL, Schafer JA, Tipton J, Metivier L. The concerns of patients and spouses after the diagnosis of colon cancer: a qualitative analysis. J Wound Ostomy Continence Nurs 1999;26:8-17.

47 Nijboer C, Triemstra M, Tempelaar R, Sanderman R, van den Bos GA. Determinants of caregiving experiences and mental health of partners of cancer patients. Cancer 1999;86:577-88. [section 3.1] [section 3.2]

48 Sprangers MAG, Taal BG, Aaronson NK, de Velde A. Quality of life in colorectal cancer. Stoma vs nonstoma patients. Dis Colon Rectum 1995;38:361-9.

49 Camilleri-Brennan J, Steele RJC. Quality of life after treatment for rectal cancer. Br J Surg 1998;85:1036-43.

50 Bekkers MJ, van Knippenberg FC, van Dulmen AM, van den Borne HW, van Berge Henegouwen GP. Survival and psychosocial adjustment to stoma surgery and nonstoma bowel resection: a 4-year follow-up. J Psychosom Res 1997;42:235-44.

51 Knowles G, Tierney A, Jodrell D, Cull A. The perceived information needs of patients receiving adjuvant chemotherapy for surgically resected colorectal cancer. Eur J Oncol Nurs 1999;13:208-22. [section 3.1] [section 3.2]

52 Jenkins V, Fallowfield L, Saul J. Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 2001;84:48-51.

53 Fallowfield L, Saul J, Gilligan B. Teaching senior nurses how to teach communication skills in oncology. Cancer Nurs 2001;24:185-91.

54 Scott JT, Entwistle VA, Sowden AJ, Watt I. Recordings or summaries of consultations for people with cancer (Cochrane Review). In: The Cochrane Library, Issue 4, 2002. Oxford: Update Software.

55 Jones R, Pearson J, McGregor S, Cawsey A, Barrett A, Craig N, et al. Randomised trial of personalised computer based information for cancer patients. BMJ 1999;319:1241-7.

56 Bruera E, Pituskin E, Calder K, Neumann CM, Hanson J. The addition of an audiocassette recording of a consultation to written recommendations for patients with advanced cancer: a randomized, controlled trial. Cancer 1999;86:2420-5.

57 Bekker H, Thornton JG, Airey CM, Connelly JB, Hewison J, Robinson MB, et al. Informed decision making: an annotated bibliography and systematic review. Health Technol Assess 1999;3:1-156. [cited 5 Nov 2002]. Available from url: http://www.hta.nhsweb.nhs.uk/fullmono/mon301.pdf

58 Beaver K, Bogg J, Luker KA. Decision-making role preferences and information needs: a comparison of colorectal and breast cancer. Health Expect 1999;2:266-76.

59 Scottish Cancer Co-ordinating and Advisory Committee. Commissioning Cancer Services Sub-Committee. Interim report to the Chief Medical Officer, SODoH. Edinburgh: The Scottish Office; 1995.

60 Clinical Standards Board for Scotland. Clinical standards: colorectal cancer. Edinburgh: The Board; 2001. [cited 5 Nov 2002]. Available from url: http://www.clinicalstandards.org/pdf/finalstand/COLORECTAL.pdf

61 Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331:1669-74.

62 Scottish Cancer Group. Cancer Genetics Sub-Group. Cancer genetics services in Scotland: guidance to support the implementation of genetic services for breast, ovarian and colorectal cancer predisposition. Edinburgh: The Scottish Executive; 2001. [cited 3 Jul 2002]. Available from url: http://www.show.scot.nhs.uk/sehd/mels/HDL2001_24GuideFull.pdf

63 Kune GA, Kune S, Watson LF. The role of heredity in the etiology of large bowel cancer: data from the Melbourne Colorectal Cancer Study. World J Surg 1989;13:124-9.

64 Lynch HT, Kimberling W, Albano WA, Lynch JF, Biscone K, Schuelke GS, et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer 1985;56:934-8.

65 Guillem JG, Forde KA, Treat MR, Neugut AI, O’Toole KM, Diamond BE. Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study. Dis Colon Rectum 1992;35:523-9.

66 Brewer DA, Fung CL, Chapuis PH, Bokey EL. Should relatives of patients with colorectal cancer be screened? A critical review of the literature. Dis Colon Rectum 1994;37:1328-38.

67 Dowling DJ, St John DJ, Macrae FA, Hopper JL. Yield from colonoscopic screening in people with a strong family history of common colorectal cancer. J Gastroenterol Hepatol 2000;15:939-44.

68 Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-5.

69 Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-6.

70 Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.

71 Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der Klift H, Mulder A, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998;339:511-8.

72 Cravo ML, Fidalgo PO, Lage PA, Albuquerque CM, Chaves PP, Claro I, et al. Validation and simplification of Bethesda guidelines for identifying apparently sporadic forms of colorectal carcinoma with microsatellite instability. Cancer 1999;85:779-85.

73 Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE. Sensitivity and specificity of clinical criteria for hereditary non- polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000;37:641-5.

74 Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.

75 Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-7.

76 Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-7. [section 4.2] [section 4.3]

77 Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-10.

78 Bishop DT, Hall NR. The genetics of colorectal cancer. Eur J Cancer 1994;30A:1946-56.

79 Rhodes M, Bradburn DM. Overview of screening and management of familial adenomatous polyposis. Gut 1992;33:125-31.

80 NHS Executive. Cancer referral guidelines: referral guidelines for suspected cancer. London: The Executive; 2000. (Health Service circular HSC 2000/013). [cited 27 Jul 2004]. Available from url: http://www.dh.gov.uk/assetRoot/04/01/22/53/04012253.pdf

81 Fijten GH, Starmans R, Muris JW, Schouten HJ, Blijham GH, Knottnerus JA. Predictive value of signs and symptoms for colorectal cancer in patients with rectal bleeding in general practice. Fam Pract 1995;12:279-86.

82 Norrelund N, Norrelund H. Colorectal cancer and polyps in patients aged 40 years and over who consult a GP with rectal bleeding. Fam Pract 1996;13:160-5.

83 Crosland A, Jones R. Rectal bleeding: prevalence and consultation behaviour. BMJ 1995;311:486-8. [section 5.1] [section 5.3]

84 Helfand M, Marton KI, Zimmer-Gembeck MJ, Sox HC Jr. History of visible rectal bleeding in a primary care population. Initial assessment and 10-year follow-up. JAMA 1997;277:44-8.

85 Stellon AJ, Kenwright SE. Iron deficiency anaemia in general practice: presentations and investigations. Br J Clin Pract 1997;51:78-80.

86 Scottish Executive. Scottish referral guidelines for suspected cancer. Edinburgh: The Executive; 2002. [cited 3 Jul 2002]. Available from url: http://www.scotland.gov.uk/library5/health/rgsc.pdf

87 Potter MA, Wilson RG. Diagnostic delay in colorectal cancer. J R Coll Surg Edinb 1999;44:313-6. [section 5.2] [section 5.3]

88 Goodman D, Irvin TT. Delay in the diagnosis and prognosis of carcinoma of the right colon. Br J Surg 1993;80:1327-9. [section 5.2] [section 5.3]

89 Mor V, Masterson-Allen S, Goldberg R, Guadagnoli E, Wool MS. Pre-diagnostic symptom recognition and help seeking among cancer patients. J Community Health 1990;15:253-66.

90 Holliday HW, Hardcastle JD. Delay in diagnosis and treatment of symptomatic colorectal cancer. Lancet 1979;1:309-11.

91 Carter S, Winslet M. Delay in the presentation of colorectal carcinoma: a review of causation. Int J Colorectal Dis 1998;13:27-31.

92 Rex DK, Weddle RA, Lehman GA, Pound DC, O’Connor KW, Hawes RH, et al. Flexible sigmoidoscopy plus air contrast barium enema versus colonoscopy for suspected lower gastrointestinal bleeding. Gastroenterology 1990;98:855-61.

93 Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000;342:1766-72.

94 de Zwart IM, Griffioen G, Shaw MP, Lamers CB, de Roos A. Barium enema and endoscopy for the detection of colorectal neoplasia: sensitivity, specificity, complications and its determinants. Clin Radiol 2001;56:401-9.

95 Flexible sigmoidoscopy. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 1998;48:695-6.

96 Winnan G, Berci G, Panish J, Talbot TM, Overholt BF, McCallum RW. Superiority of the flexible to the rigid sigmoidoscope in routine proctosigmoidoscopy. N Engl J Med 1980;302:1011-2.

97 Rex DK, Rahmani EY, Haseman JH, Lemmel GT, Kaster S, Buckley JS. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 1997;112:17-23.

98 Thoeni RF, Laufer I. Polyps and cancer. In: Gore R, Levine MS, Laufer I, editors. Textbook of gastrointestinal radiology. Philadelphia: WB Saunders; 1994. p. 1160. [section 6.1] [section 6.2] [section 6.3]

99 Bartram CI. The colon and rectum. In: Curati WL, Cosgrove DO, Lipton MJ, Allison DJ, editors. Imaging in oncology. London: Greenwich Medical Media; 1998. p. 99-110.

100 Atkin W. Implementing screening for colorectal cancer. BMJ 1999;319:1212-3.

101 Waye JD, Kahn O, Auerbach ME. Complications of colonoscopy and flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 1996;6:343-77.

102 Kewenter J, Brevinge H, Engaras B, Haglind E. The yield of flexible sigmoidoscopy and double-contrast barium enema in the diagnosis of neoplasms in the large bowel in patients with a positive Hemoccult test. Endoscopy 1995;27:159-63.

103 Blakeborough A, Sheridan MB, Chapman AH. Complications of barium enema examinations: a survey of UK Consultant Radiologists 1992 to 1994. Clin Radiol 1997;52:142-8.

104 Connolly DJ, Traill ZC, Reid HS, Copley SJ, Nolan DJ. The double contrast barium enema: a retrospective single centre audit of the detection of colorectal carcinomas. Clin Radiol 2002;57:29-32.

105 Jensen J, Kewenter J, Asztely M, Lycke G, Wojciechowski J. Double contrast barium enema and flexible rectosigmoidoscopy: a reliable diagnostic combination for detection of colorectal neoplasm. Br J Surg 1990;77:270-2.

106 Miao YM, Amin Z, Healy J, Burn P, Murugan N, Westaby D, et al. A prospective single centre study comparing computed tomography pneumocolon against colonoscopy in the detection of colorectal neoplasms. Gut 2000;47:832-7.

107 McFarland EG, Brink JA. Helical CT colonography (virtual colonoscopy): the challenge that exists between advancing technology and generalizability. AJR Am J Roentgenol 1999;173:549-59.

108 Stevenson GW. Colorectal cancer imaging: a challenge for radiologists. Radiology 2000;214:615-21.

109 Heriot AG, Grundy A, Kumar D. Preoperative staging of rectal carcinoma. Br J Surg 1999;86:17-28.

110 Knol JA, Marn CS, Francis IR, Rubin JM, Bromberg J, Chang AE. Comparisons of dynamic infusion and delayed computed tomography, intraoperative ultrasound and palpation in the diagnosis of liver metastases. Am J Surg 1993;165:81-7.

111 Kwok H, Bissett IP, Hill GL. Preoperative staging of rectal cancer. Int J Colorectal Dis 2000;15:9-20.

112 Beets-Tan RG, Beets GL, Vliegen RF, Kessels AG, Van Boven H, De Bruine A, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001;357:497-504.

113 Williams NS, Jass JR, Hardcastle JD. Clinicopathological assessment and staging of colorectal cancer. Br J Surg 1988;75:649-52.

114 Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism. Edinburgh: SIGN; 2002. (SIGN publication no. 62).

115 Scottish Intercollegiate Guidelines Network (SIGN). Antibiotic prophylaxis in surgery. Edinburgh: SIGN; 2000. (SIGN publication no. 45).

116 Glenny AM, Song F. Antimicrobial prophylaxis in colorectal surgery. Qual Health Care 1999;8:132-6.

117 Burke P, Mealy K, Gillen P, Joyce W, Traynor O, Hyland J. Requirement for bowel preparation in colorectal surgery. Br J Surg 1994;81:907-10.

118 Santos JC Jr, Batista J, Sirimarco MT, Guimaraes AS, Levy CE. Prospective randomized trial of mechanical bowel preparation in patients undergoing elective colorectal surgery. Br J Surg 1994;81:1673-6.

119 Miettinen RP, Laitinen ST, Makela JT, Paakkonen ME. Bowel preparation with oral polyethylene glycol electrolyte solution vs. no preparation in elective open colorectal surgery: prospective, randomized study. Dis Colon Rectum 2000;43:669-75.

120 Foster RS, Costanza MC, Foster JC, Wanner MC, Foster CB. Adverse relationship between blood transfusions and survival after colectomy for colon cancer. Cancer 1985;55:1195-201.

121 McAlister FA, Clark HD, Wells PS, Laupacis A. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg 1998;85:171-8.

122 Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998;133:894-9.

123 Wiig JN, Carlsen E, Soreide O. Mesorectal excision for rectal cancer: a view from Europe. Semin Surg Oncol 1998;15:78-86.

124 Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000;356:93-6. [section 7.4.1] [section 7.9]

125 Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994;344:707-11.

126 Lewis WG, Martin IG, Williamson ME, Stephenson BM, Holdsworth PJ, Finan PJ, et al. Why do some patients experience poor functional results after anterior resection of the rectum for carcinoma? Dis Colon Rectum 1995;38:259-63.

127 Havenga K, Maas CP, DeRuiter MC, Welvaart K, Trimbos JB. Avoiding long-term disturbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. Semin Surg Oncol 2000;18:235-43.

128 Wiggers T, Jeekel J, Arends JW, Brinkhorst AP, Kluck HM, Luyk CI. No-touch isolation technique in colon cancer: a controlled prospective trial. Br J Surg 1988;75:409-15.

129 Rouffet F, Hay JM, Vacher B, Fingerhut A, Elhadad A, Flamant Y, et al. Curative resection for left colonic carcinoma: hemicolectomy vs. segmental colectomy. A prospective, controlled, multicenter trial. French Association for Surgical Research. Dis Colon Rectum 1994;37:651-9.

130 MacRae HM, McLeod RS. Handsewn vs. stapled anastomoses in colon and rectal surgery: a meta- analysis. Dis Colon Rectum 1998;41:180-9.

131 Rullier E, Laurent C, Garrelon JL, Michel P, Saric J, Parneix M. Risk factors for anastomotic leakage after resection of rectal cancer. B J Surg 1998;85:355-8.

132 Dehni N, Schlegel RD, Cunningham C, Guiguet M, Tiret E, Parc R. Influence of a defunctioning stoma on leakage rates after low colorectal anastomosis and colonic J pouch-anal anastomosis. Br J Surg 1998;85:1114-7.

133 Williams N, Seow-Choen F. Physiological and functional outcome following ultra-low anterior resection with colon pouch-anal anastomosis. Br J Surg 1998;85:1029-35.

134 Huber FT, Herter B, Siewert JR. Colonic pouch vs. side-to-end anastomosis in low anterior resection. Dis Colon Rectum 1999;42:896-902.

135 Ho YH, Tan M, Leong A, Seow-Choen F. Ambulatory manometry in patients with colonic J-pouch and straight coloanal anastomoses: randomized, controlled trial. Dis Colon Rectum 2000;43:793-9.

136 Winde G, Nottberg H, Keller R, Schmid KW, Bunte H. Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection. Dis Colon Rectum 1996;39:969-76.

137 Breen E, Bleday R. Preservation of the anus in the therapy of distal rectal cancers. Surg Clin North Amer 1997;77:71-83.

138 Kikuchi R, Takano M, Takagi K, Fujimoto N, Nozaki R, Fujiyoshi T, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum 1995;38:1286-95.

139 Wolff WL, Shinya H, Cwern M, Hsu M. Cancerous colonic polyps. “Hands on” or “hands off?”. Am Surg 1990;56:148-52.

140 Chapman MAS, Scholefield JH, Hardcastle JD. Management and outcome of patients with malignant colonic polyps identified from the Nottingham Colorectal Screening Study. Colorectal Dis 2000;2:8-12.

141 Maxwell-Armstrong CA, Robinson MH, Scholefield JH. Laparoscopic colorectal cancer surgery. Am J Surg 2000;179:500-7.

142 Koruth NM, Koruth A, Matheson NA. The place of contrast enema in the management of large bowel obstruction. J R Coll Surg Edinb 1985;30:258-60.

143 Deans GT, Krukowski ZH, Irwin ST. Malignant obstruction of the left colon. Br J Surg 1994;81:1270-6.

144 Single-stage treatment for malignant left-sided colonic obstruction: a prospective randomized clinical trial comparing subtotal colectomy with segmental resection following intraoperative irrigation. The SCOTIA Study Group. Subtotal Colectomy versus On-table Irrigation and Anastomosis. Br J Surg 1995;82:1622-7.

145 Lo SK. Metallic stenting for colorectal obstruction. Gastrointest Endosc Clin N Am 1999;9:459-77.

146 Camunez F, Echenagusia A, Simo G, Turegano F, Vazquez J, Barreiro-Meiro I. Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation. Radiology 2000; 216:492-7.

147 Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59-71.

148 Shirouzu K, Isomoto H, Hayashi A, Nagamatsu Y, Kakegawa T. Surgical treatment for patients with pulmonary metastases after resection of primary colorectal carcinoma. Cancer 1995;76:393-8.

149 Seifert JK, Junginger T, Morris DL. A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Edinb 1998;43:141-54.

150 Sagar PM, Pemberton JH. Surgical management of locally recurrent rectal cancer. Br J Surg 1996;83:293-304.

151 Dohmoto M, Hunerbein M, Schlag PM. Palliative endoscopic therapy of rectal carcinoma. Eur J Cancer 1996;32A:25-9.

152 Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 2000;18:2327-40.

153 Meagher AP. Colorectal cancer: is the surgeon a prognostic factor? A systematic review. Med J Austr 1999;171:308-10.

154 Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: A prospective evaluation. Gastroenterology 1997;112:1096-102.

155 Talbot IC, Ritchie S, Leighton MH, Hughes AO, Bussey HJR, Morson BC. The clinical significance of invasion of veins by rectal cancer. Br J Surg 1980; 67:439-42.

156 Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994;344:707-11.

157 Cross SS, Feeley KM, Angel CA. The effect of four interventions on the informational content of histopathology reports of resected colorectal carcinomas. J Clin Pathol 1998;51:481-2.

158 Branston LK, Greening S, Newcombe RG, Daoud R, Abraham JM, Wood F, et al. The implementation of guidelines and computerised forms improves the completeness of cancer pathology reporting. The CROPS project: a randomised controlled trial in pathology. Eur J Cancer 2002;38:764-72.

159 Joint Council for Clinical Oncology. Quality control in cancer chemotherapy: managerial and procedural aspects. London: Royal College of Physicians. Royal College of Radiologists; 1994.

160 Scottish Executive Health Department. Guidelines for the use of cytotoxic chemotherapy in the clinical environment. Edinburgh: The Department; 2001. (NHS HDL (2001)13). [cited 3 Jul 2002]. Available from url: http://www.show.scot.nhs.uk/sehd/mels/HDL2001_13.htm

161 Figueredo A, Fine S, Maroun J, Walker-Dilks C, Wong S. Adjuvant therapy for stage III colon cancer after complete resection. Cancer Prev Control 1997; 1:304-19. [section 9.1] [section 9.1.3]

162 O’Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246-50. [section 9.1] [section 9.1.3]

163 Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-44.

164 Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 1997;40:35-41.

165 Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000;355:1588-96.

166 Harris V, Sandridge AL, Black RJ, Brewster DH, Gould A. Cancer registration statistics Scotland 1986-1995. Edinburgh: ISD Scotland Publications; 1998.

167 Figueredo A, Germond C, Maroun J, Browman G, Walker-Dilks C, Wong S. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1997;1:379-92.

168 Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group. J Natl Cancer Inst 1997;89:497-505.

169 Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK). Lancet 1995;345:349-53.

170 Rougier P, Sahmoud T, Nitti D, Curran D, Doci R, De Waele B, et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research. Lancet 1998;351:1677-81.

171 James RD. AXIS: intraportal 5FU and peri-operative radiotherapy in the adjuvant treatment of colorectal cancer - results of the UKCCCR trial. Br J Cancer 1999;80(Suppl 2):20.

172 Scheithauer W, Kornek GV, Marczell A, Karner J, Salem G, Greiner R, et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer 1998;77:1349 54.

173 Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, et al. Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.

174 Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, et al. Edrecolomab (17-1A Antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a phase III study [abstract]. ASCO Abstracts 2001;20:Abstract 487.

175 Seymour MT, Slevin ML, Kerr DJ, Cunningham D, James RD, Ledermann JA, et al. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol 1996;14:2280-8. [section 9.1.2] [section 9.3.6]

176 Hill M, Norman A, Cunningham D, Findlay M, Watson M, Nicolson V, et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumour response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 1995;13:2317-23. [section 9.1.2] [section 9.3.6]

177 Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553-9.

178 Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB 3rd, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000;18:148-57.

179 Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000;355:1588-96.

180 Kerr DJ, Gray R, McConkey C, Barnwell J. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules—less pain, same gain. QUASAR Colorectal Cancer Study Group. Ann Oncol 2000;11:947-55.

181 Saini A, Cunningham D, Norman AR, Hill ME, Tait D, Hickish T, et al. Multicentre randomized trial of protracted venous infusion (PVI) 5 FU compared to 5 FU/folinic acid (5FU/FA) as adjuvant therapy for colorectal cancer [abstract]. ASCO Abstracts 2000;19:Abstract 928.

182 Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92. [section 9.1.3] [section 9.3.2]

183 Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 2000;284:1008-15.

184 Munro AJ, Bentley AHM. Adjuvant radiotherapy in operable rectal cancer: a systematic review. Semin Colon Rectal Surg 2002;13:31-42.

185 Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980-7.

186 Dahlberg M, Glimelius B, Graf W, Pahlman L. Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum 1998;41:543-9.

187 Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001;358:1291-304.

188 Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer 1995;75:2269-75.

189 Holm T, Singnomklao T, Rutqvist LE, Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer 1996;78:968-76.

190 Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.

191 Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993;36:564-72.

192 Glimelius B, Isacsson U, Jung B, Pahlman L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment. Int J Radiat Oncol Biol Phys 1997;37:281-7.

193 Bosset JF, Pavy JJ, Hamers HP, Horiot JC, Fabri MC, Rougier P, et al. Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group. Eur J Cancer 1993;29A:1406-10.

194 Rich TA, Skibber JM, Ajani JA, Buchholz DJ, Cleary KR, Dubrow RA, et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 1995;32:1025-9.

195 Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.

196 Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986;2:996-9.

197 Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Medical Research Council Rectal Cancer Working Party. Lancet 1996;348:1605-10.

198 Marsh PJ, James RD, Schofield PF. Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial. Dis Colon Rectum 1994;37:1205-14.

199 Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000;321:531-5. [section 9.3] [section 9.3.1]

200 Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000;82:1789-94. [section 9.3] [section 9.3.1]

201 Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, et al. ‘Tomudex’ (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The ‘Tomudex’ Colorectal Cancer Study Group. Eur J Cancer 1995; 31A:1945-54.

202 de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15.

203 Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998;16:2943-52.

204 Pazdur R, Douillard JY, Skillings JR, Eisenberg PD, Davidson N, Harper P, et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFTTM in combination with leucovorin (LV) in patients with metastatic colorectal cancer [abstract]. ASCO Abstracts 1999;18:Abstract 1009.

205 Efficacy of intravenous continuous infusion of flourouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol 1998;16:301-8.

206 Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32.

207 de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15.

208 Zalcberg J. Overview of the tolerability of ‘Tomudex’ (raltitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997;8:S17-22.

209 Cunningham D. Mature results from three large controlled studies with raltitrexed (‘Tomudex’). Br J Cancer 1998;77:15-21.

210 Stephens RJ, Hopwood P, Johnston C, Maughan TS. The value of quality of life (QL) outcomes in comparing 3 chemotherapy regimens (de Gramont, lokich and raltitrexed) in a multicentre randomised trial of metastatic colorectal cancer [abstract]. ASCO Abstracts 1999;18:Abstract 2220.

211 Drug-company decision to end cancer trial. Lancet 1999;354:1045.

212 Judson I, Maughan T, Beale P, Primrose J, Hoskin P, Hanwell J, et al. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694). Br J Cancer 1998;78:1188-93.

213 Köhne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, et al. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 1998; 77:973-7.

214 Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1555-63.

215 Carmichael J, Popiela T, Radstone D, Falk S, Fey M, Oza A, et al. Randomized comparative study of ORZEL(r) (oral uracil/tegafur (UFTTM) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer [abstract]. ASCO Abstracts 1999;18:Abstract 1015.

216 Health Technology Board for Scotland. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Understanding HTBS advice. Glasgow: The Board; 2002. [cited 27 Jul 2004]. Available from url: http://docs.scottishmedicines.org/docs/pdf/HTBS%20ADVICE-COLORECTAL%20A5.pdf

217 Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.

218 Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.

219 Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.

220 de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.

221 Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995-1001.

222 Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8:347-53.

223 Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996; 78:1639-45.

224 Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996;88:252-8.

225 Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;18:243-54.

226 Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48.

227 Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.

228 Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12.

229 Maxwell-Armstrong CA, Durrant LG, Buckley TJD, Scholefield JH, Robins RA, Fielding K, et al. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer 2001:84;1443-6.

230 Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997; 350:681-6.

231 Habr-Gama A, de Souza PM, Ribeiro U Jr, Nadalin W, Gansl R, Sousa AH Jr, et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998;41:1087-96.

232 Chari RS, Tyler DS, Anscher MS, Russell L, Clary BM, Hathorn J, et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 1995;221:778-87.

233 Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Reichman B, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992;10:79-84.

234 Bosset JF, Magnin V, Maingon P, Mantion G, Pelissier EP, Mercier M, et al. Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. Int J Radiat Oncol Biol Phys 2000;46:323-7.

235 Ngan SY, Burmeister BH, Fisher R, Rischin D, Schache DJ, Kneebone A, et al. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2001;50:883-7.

236 Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001;24:107-12.

237 Spanos WJJ, Perez CA, Marcus S, Poulter CA, Doggett RL, Steinfeld AD, et al. Effect of rest interval on tumour and normal tissue response - a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502). Int J Radiat Oncol Biol Phys 1993;25:399-403.

238 Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5- year survival of colorectal cancer patients. Gastroenterology 1998;114:7-14.

239 Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: A prospective, randomized study. Dis Colon Rectum 1998;41:1127-33.

240 Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 1997;84:666-9.

241 Audisio RA, Setti-Carraro P, Segala M, Capko D, Andreoni B, Tiberio G. Follow-up in colorectal cancer patients: a cost-benefit analysis. Ann Surg Oncol 1996;3:349-57.

242 Secco GB, Fardelli R, Rovida S, Gianquinto D, Baldi E, Bonfante P, et al. Is intensive follow-up really able to improve prognosis of patients with local recurrence after curative surgery for rectal cancer? Ann Surg Oncol 2000; 7:32-7.

243 Rosen M, Chan L, Beart RW Jr, Vukasin P, Anthone G. Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum 1998;41:1116-26.

244 Renehan AG, Egger ME, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow-up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:1-8.

245 Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software.

246 Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998;41:1127-33.

247 McCarthy EP, Phillips RS, Zhong Z, Drews RE, Lynn J. Dying with cancer: patients’ function, symptoms and care preferences as death approaches. J Am Geriatr Soc 2000;48:S110-21.

248 Twycross R, Wilcock A. Symptom management in advanced cancer. 3rd ed. Abingdon: Radcliffe Medical Press; 2001.

249 Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Coyle N, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994;3:183-9.

250 Scottish Executive Health Department. Scottish national audit of the prevalence of pain in patients with active cancers recognised to cause pain. Edinburgh; Cancer in Scotland: 2003. [cited 6 Mar 2003] .Available from url: http://www.show.scot.nhs.uk/sehd/cancerinscotland

251 Scottish Intercollegiate Guidelines Network (SIGN). Control of pain in patients with cancer. Edinburgh: SIGN; 2000. (SIGN publication no. 44).

252 Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001;9:223-33.

253 Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software.

254 Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000;11:971-5.

255 Bruera E, Ernst S, Hagen N, Spachynski K, Belzile M, Hanson J, et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998;2:74-8.

256 Fearon KC, Barber MD, Moses AG. The cancer cachexia syndrome. Surg Oncol Clin N Am 2001;10:109-26.